Cost burden of diffuse large B-cell lymphoma

R. Andrew Harkins; Sharvil P. Patel; Christopher R. Flowers

doi:10.1080/14737167.2019.1680288

Cost burden of diffuse large B-cell lymphoma

R. Andrew Harkins, Sharvil P. Patel, Christopher R. Flowers

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and is a clinically heterogeneous disease. Treatment pathways for DLBCL are diverse and integrate established and novel therapies. Areas covered: We review the cost burden of DLBCL and the cost-effectiveness of DLBCL management including precision and cellular medicine. We utilized Medical Subject Heading (MeSH) terms and keywords to search the National Library of Medicine online MEDLINE database (PubMed) for articles related to cost, cost burden, and cost-of-illness of DLBCL and cost-effectiveness of DLBCL management strategies published in English as of June 2019. Expert commentary: Available and developing DLBCL therapies offer improved outcomes and often curative treatment at considerable financial expense, and the total cost burden for DLBCL management is substantial for patients and the healthcare system. In the era of personalized medicine, CAR T cells and targeted therapies provide exciting avenues for current and future DLBCL care and can further increase treatment cost. Determinations of cost and cost-effectiveness in DLBCL treatment pathways should continue to guide care providers and systems in identifying cost reduction strategies to provide appropriate therapies to the greatest number of patients in treating DLBCL.

Original language	English (US)
Pages (from-to)	645-661
Number of pages	17
Journal	Expert Review of Pharmacoeconomics and Outcomes Research
Volume	19
Issue number	6
DOIs	https://doi.org/10.1080/14737167.2019.1680288
State	Published - Nov 2 2019
Externally published	Yes

Keywords

B-cell lymphoma
DLBCL
NHL
cost
cost-effectiveness
diffuse large B-cell lymphoma
non-Hodgkin lymphoma

ASJC Scopus subject areas

Health Policy
Pharmacology (medical)

Access to Document

10.1080/14737167.2019.1680288

Cite this

@article{298752ffb0f6426a8163106ae09ce7bf,

title = "Cost burden of diffuse large B-cell lymphoma",

abstract = "Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and is a clinically heterogeneous disease. Treatment pathways for DLBCL are diverse and integrate established and novel therapies. Areas covered: We review the cost burden of DLBCL and the cost-effectiveness of DLBCL management including precision and cellular medicine. We utilized Medical Subject Heading (MeSH) terms and keywords to search the National Library of Medicine online MEDLINE database (PubMed) for articles related to cost, cost burden, and cost-of-illness of DLBCL and cost-effectiveness of DLBCL management strategies published in English as of June 2019. Expert commentary: Available and developing DLBCL therapies offer improved outcomes and often curative treatment at considerable financial expense, and the total cost burden for DLBCL management is substantial for patients and the healthcare system. In the era of personalized medicine, CAR T cells and targeted therapies provide exciting avenues for current and future DLBCL care and can further increase treatment cost. Determinations of cost and cost-effectiveness in DLBCL treatment pathways should continue to guide care providers and systems in identifying cost reduction strategies to provide appropriate therapies to the greatest number of patients in treating DLBCL.",

keywords = "B-cell lymphoma, DLBCL, NHL, cost, cost-effectiveness, diffuse large B-cell lymphoma, non-Hodgkin lymphoma",

author = "Harkins, {R. Andrew} and Patel, {Sharvil P.} and Flowers, {Christopher R.}",

note = "Funding Information: In a study comparing axicabtagene ciloleucel to salvage chemotherapy using a decision model, the base-case analysis identified lifetime costs for CAR T-cell therapy at roughly $550,000 and salvage chemotherapy at approximately $170,000 []. In this study, Axicabtagene ciloleucel exhibited an ICER of $58,000/QALY gained. The authors note that the significant differences in ICER observed in this study in comparison with the study from the Institute for Clinical and Economic Review were due to survival modeling methods. The decision model exhibited sensitivity to percentage of patients in long-term remission, outcome discount rate, and drug cost. Notably, this study was funded by Kite, the pharmaceutical company producing axicabtagene ciloleucel. Publisher Copyright: {\textcopyright} 2019, {\textcopyright} 2019 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2019",

month = nov,

day = "2",

doi = "10.1080/14737167.2019.1680288",

language = "English (US)",

volume = "19",

pages = "645--661",

journal = "Expert Review of Pharmacoeconomics and Outcomes Research",

issn = "1473-7167",

publisher = "Expert Reviews Ltd.",

number = "6",

}

TY - JOUR

T1 - Cost burden of diffuse large B-cell lymphoma

AU - Harkins, R. Andrew

AU - Patel, Sharvil P.

AU - Flowers, Christopher R.

N1 - Funding Information: In a study comparing axicabtagene ciloleucel to salvage chemotherapy using a decision model, the base-case analysis identified lifetime costs for CAR T-cell therapy at roughly $550,000 and salvage chemotherapy at approximately $170,000 []. In this study, Axicabtagene ciloleucel exhibited an ICER of $58,000/QALY gained. The authors note that the significant differences in ICER observed in this study in comparison with the study from the Institute for Clinical and Economic Review were due to survival modeling methods. The decision model exhibited sensitivity to percentage of patients in long-term remission, outcome discount rate, and drug cost. Notably, this study was funded by Kite, the pharmaceutical company producing axicabtagene ciloleucel. Publisher Copyright: © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.

PY - 2019/11/2

Y1 - 2019/11/2

N2 - Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and is a clinically heterogeneous disease. Treatment pathways for DLBCL are diverse and integrate established and novel therapies. Areas covered: We review the cost burden of DLBCL and the cost-effectiveness of DLBCL management including precision and cellular medicine. We utilized Medical Subject Heading (MeSH) terms and keywords to search the National Library of Medicine online MEDLINE database (PubMed) for articles related to cost, cost burden, and cost-of-illness of DLBCL and cost-effectiveness of DLBCL management strategies published in English as of June 2019. Expert commentary: Available and developing DLBCL therapies offer improved outcomes and often curative treatment at considerable financial expense, and the total cost burden for DLBCL management is substantial for patients and the healthcare system. In the era of personalized medicine, CAR T cells and targeted therapies provide exciting avenues for current and future DLBCL care and can further increase treatment cost. Determinations of cost and cost-effectiveness in DLBCL treatment pathways should continue to guide care providers and systems in identifying cost reduction strategies to provide appropriate therapies to the greatest number of patients in treating DLBCL.

AB - Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and is a clinically heterogeneous disease. Treatment pathways for DLBCL are diverse and integrate established and novel therapies. Areas covered: We review the cost burden of DLBCL and the cost-effectiveness of DLBCL management including precision and cellular medicine. We utilized Medical Subject Heading (MeSH) terms and keywords to search the National Library of Medicine online MEDLINE database (PubMed) for articles related to cost, cost burden, and cost-of-illness of DLBCL and cost-effectiveness of DLBCL management strategies published in English as of June 2019. Expert commentary: Available and developing DLBCL therapies offer improved outcomes and often curative treatment at considerable financial expense, and the total cost burden for DLBCL management is substantial for patients and the healthcare system. In the era of personalized medicine, CAR T cells and targeted therapies provide exciting avenues for current and future DLBCL care and can further increase treatment cost. Determinations of cost and cost-effectiveness in DLBCL treatment pathways should continue to guide care providers and systems in identifying cost reduction strategies to provide appropriate therapies to the greatest number of patients in treating DLBCL.

KW - B-cell lymphoma

KW - DLBCL

KW - NHL

KW - cost

KW - cost-effectiveness

KW - diffuse large B-cell lymphoma

KW - non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85075620842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075620842&partnerID=8YFLogxK

U2 - 10.1080/14737167.2019.1680288

DO - 10.1080/14737167.2019.1680288

M3 - Review article

C2 - 31623476

AN - SCOPUS:85075620842

SN - 1473-7167

VL - 19

SP - 645

EP - 661

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

IS - 6

ER -

Cost burden of diffuse large B-cell lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this